Epigenetics within the matrix, a neo-regulator of fibrotic disease

Epigenetics

Volumn 7, Issue 9, 2012, Pages 987-993

  Robinson, Claire M ^a   Watson, Chris J ^a   Baugh, John A ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

5 aza 2' deoxycytidine; DNA methylation; Fibrosis; Histone deacetylase inhibitors; Histone modification; Myofibroblast

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYL CYTOSINE; AZACITIDINE; CYCLOOXYGENASE 2; CYTOSINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; INTERLEUKIN 6; METHYL CPG BINDING PROTEIN 2; METHYLTRANSFERASE INHIBITOR; PROTEIN LYSINE 6 OXIDASE; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

ALLERGIC REACTION; ANGIOGENESIS; AUTOIMMUNE DISEASE; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMICAL INJURY; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; EMPHYSEMA; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GENE SILENCING; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTONE MODIFICATION; HUMAN; HYPOXIA; LUNG CANCER; MYELODYSPLASTIC SYNDROME; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PERSISTENT INFECTION; PROTEIN EXPRESSION; RADIATION INJURY; REVIEW; TISSUE INJURY; WOUND HEALING;

EID: 84866057211     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.21567     Document Type: Review

References (69)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199-210; http://dx.doi.org/10.1002/path.2277.
2. Mehal WZ, Iredale J, Friedman SL. Scraping fibro-sis: expressway to the core of fibrosis. Nat Med 2011; 17:552-3; http://dx.doi.org/10.1038/nm0511-552.
3. Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc 2008; 5:334-7; http://dx.doi.org/10.1513/pats.200708-146DR.
4. Darby IA, Hewitson TD. Fibroblast differentia-tion in wound healing and fibrosis. Int Rev Cytol 2007; 257:143-79; http://dx.doi.org/10.1016/S0074-7696(07)57004-X.
5. Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012; 27:183-93; http://dx.doi.org/10.1007/s00467-011-1772-6.
6. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146:56-66;
7. Jordana M, Schulman J, McSharry C, Irving LB, Newhouse MT, Jordana G, et al. Heterogeneous pro-liferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988; 137:579-84;
8. Hetzel M, Bachem M, Anders D, Trischler G, Faehling M. Different effects of growth factors on prolif-eration and matrix production of normal and fibrotic human lung fibroblasts. Lung 2005; 183:225-37; http://dx.doi.org/10.1007/s00408-004-2534-z.
9. Rodemann HP, Müller GA. Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med 1990; 195:57-63;
10. Rodemann HP, Müller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibro-blasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17:684-6;
11. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-63; http://dx.doi.org/10.1038/nature02625.
12. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; http://dx.doi.org/10.1093/carcin/bgp220.
13. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-803; http://dx.doi.org/10.1002/cncr.21792.
14. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-52; http://dx.doi.org/10.1634/theoncologist.12-10-1247.
15. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A 2000; 97:1778-83; http://dx.doi.org/10.1073/pnas.97.4.1778.
16. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, et al. Altered DNA Methylation Profile in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012; In press http://dx.doi.org/10.1164/rccm.201201-0077OC.
17. Komatsu Y, Waku T, Iwasaki N, Ono W, Yamaguchi C, Yanagisawa J. Global analysis of DNA meth-ylation in early-stage liver fibrosis. BMC Med Genomics 2012; 5:5; http://dx.doi.org/10.1186/1755-8794-5-5.
18. Huang SK, Fisher AS, Scruggs AM, White ES, Hogaboam CM, Richardson BC, et al. Hypermethylation of PTGER2 confers prosta-glandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol 2010; 177:2245-55; http://dx.doi.org/10.2353/ajpath.2010.100446.
19. Sanders YY, Kumbla P, Hagood JS. Enhanced myofi-broblastic differentiation and survival in Thy-1(-) lung fibroblasts. Am J Respir Cell Mol Biol 2007; 36:226-35; http://dx.doi.org/10.1165/rcmb.2006-0178OC.
20. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermeth-ylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39:610-8; http://dx.doi.org/10.1165/rcmb.2007-0322OC.
21. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16:544-50; http://dx.doi.org/10.1038/nm.2135.
22. Tao H, Huang C, Yang JJ, Ma TT, Bian EB, Zhang L, et al. MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 2011; 290:327-33; http://dx.doi.org/10.1016/j.tox.2011.10.011.
23. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271-9; http://dx.doi.org/10.1002/art.21948.
24. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA. Regulation of myofibroblast transdif-ferentiation by DNA methylation and MeCP2: impli-cations for wound healing and fibrogenesis. Cell Death Differ 2007; 14:275-85; http://dx.doi.org/10.1038/sj.cdd.4401979.
25. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferen-tiation and fibrosis. Gastroenterology 2010; 138:705-14, 714, e1-4; http://dx.doi.org/10.1053/j.gastro.2009.10.002.
26. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Essential role of MeCP2 in the regulation of myofibroblast dif-ferentiation during pulmonary fibrosis. Am J Pathol 2011; 178:1500-8; http://dx.doi.org/10.1016/j.ajpath.2011.01.002.
27. Nan X, Tate P, Li E, Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 1996; 16:414-21;
28. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is respon-sible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009; 29:4325-39; http://dx.doi.org/10.1128/MCB.01776-08.
29. Coward WR, Watts K, Feghali-Bostwick CA, Jenkins G, Pang L. Repression of IP-10 by interactions between histone deacetylation and hypermethyl-ation in idiopathic pulmonary fibrosis. Mol Cell Biol 2010; 30:2874-86; http://dx.doi.org/10.1128/MCB.01527-09.
30. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T. Histone deacetylase modu-lates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 2010; 298:F133-41; http://dx.doi.org/10.1152/ajprenal.00400.2009.
31. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, et al. Cardiac hypertrophy and his-tone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003; 112:863-71;
32. Wang Z, Chen C, Finger SN, Kwajah S, Jung M, Schwarz H, et al. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J 2009; 34:145-55; http://dx.doi.org/10.1183/09031936.00084808.
33. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 2009; 297:L864-70; http://dx.doi.org/10.1152/ajplung.00128.2009.
34. Davies ER, Haitchi HM, Thatcher TH, Sime PJ, Kottmann RM, Ganesan A, et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46:687-94; http://dx.doi.org/10.1165/rcmb.2011-0040OC.
35. Sanders YY, Tollefsbol TO, Varisco BM, Hagood JS. Epigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblasts. Am J Respir Cell Mol Biol 2011; 45:16-23; http://dx.doi.org/10.1165/rcmb.2010-0154OC.
36. Diao JS, Xia WS, Yi CG, Wang YM, Li B, Xia W, et al. Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts. Arch Dermatol Res 2011; 303:573-80; http://dx.doi.org/10.1007/s00403-011-1140-1.
37. Chen CZ, Peng YX, Wang ZB, Fish PV, Kaar JL, Koepsel RR, et al. The Scar-in-a-Jar: studying poten-tial antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol 2009; 158:1196-209; http://dx.doi.org/10.1111/j.1476-5381.2009.00387.x.
38. Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, et al. Antifibrotic activity of an inhibitor of his-tone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 2010; 159:1408-17; http://dx.doi.org/10.1111/j.1476-5381.2010.00637.x.
39. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, et al. Inhibition of histone deacet-ylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009; 297:F996-1005; http://dx.doi.org/10.1152/ajpre-nal.00282.2009.
40. Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, Robinson S, et al. The histone methyltrans-ferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology 2012; 56:1129-39; http://dx.doi.org/10.1002/hep.25754.
41. Zager RA, Johnson AC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes. Am J Physiol Renal Physiol 2009; 296:F1032-41; http://dx.doi.org/10.1152/ajprenal.00061.2009.
42. Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol 2011; 2011:197946; http://dx.doi.org/10.1155/2011/197946.
43. Mizuno S, Yasuo M, Bogaard HJ, Kraskauskas D, Natarajan R, Voelkel NF. Inhibition of histone deacety-lase causes emphysema. Am J Physiol Lung Cell Mol Physiol 2011; 300:L402-13; http://dx.doi.org/10.1152/ajplung.00207.2010.
44. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, et al. Suppression of histone deacety-lases worsens right ventricular dysfunction after pulmo-nary artery banding in rats. Am J Respir Crit Care Med 2011; 183:1402-10; http://dx.doi.org/10.1164/rccm.201007-1106OC.
45. Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, et al. TGF-β regulates DNA methyltrans-ferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS One 2011; 6:e25168; http://dx.doi.org/10.1371/journal.pone.0025168.
46. Thillainadesan G, Chitilian JM, Isovic M, Ablack JN, Mymryk JS, Tini M, et al. TGF-β-Dependent Active Demethylation and Expression of the p15(ink4b) Tumor Suppressor Are Impaired by the ZNF217/CoREST Complex. Mol Cell 2012; 46:636-49; http://dx.doi.org/10.1016/j.mol-cel.2012.03.027.
47. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22:1686-98; http://dx.doi.org/10.1091/mbc.E11-02-0103.
48. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol 2010; 177:21-8; http://dx.doi.org/10.2353/ajpath.2010.090999.
49. Yang Y, Wicks J, Haitchi HM, Powell RM, Manuyakorn W, Howarth PH, et al. Regulation of a disintegrin and metalloprotease-33 expression by transforming growth factor-β. Am J Respir Cell Mol Biol 2012; 46:633-40; http://dx.doi.org/10.1165/rcmb.2011-0030OC.
50. Wakabayashi Y, Tamiya T, Takada I, Fukaya T, Sugiyama Y, Inoue N, et al. Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-2) promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-β-Smad pathway. J Biol Chem 2011; 286:35456-65; http://dx.doi.org/10.1074/jbc.M111.236794.
51. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modu-lates fibrotic gene expression. J Am Soc Nephrol 2010; 21:2069-80; http://dx.doi.org/10.1681/ASN.2010060633.
52. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dys-function in rats. Hypertension 2010; 56:225-31; http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.148635.
53. Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 2010; 8:471-81; http://dx.doi.org/10.1158/1541-7786.MCR-09-0496.
54. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51:881-90;
55. Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 2001; 276:39508-11; http://dx.doi.org/10.1074/jbc.C100343200.
56. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58:2351-66; http://dx.doi.org/10.1046/j.1523-1755.2000.00419.x.
57. Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G, et al. Comparative expression profiling in pulmonary fibro-sis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007; 176:1108-19; http://dx.doi.org/10.1164/rccm.200705-683OC.
58. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithe-lial-to-mesenchymal transition. J Clin Invest 2007; 117:3810-20;
59. Short M, Nemenoff RA, Zawada WM, Stenmark KR, Das M. Hypoxia induces differentiation of pul-monary artery adventitial fibroblasts into myofibro-blasts. Am J Physiol Cell Physiol 2004; 286:C416-25; http://dx.doi.org/10.1152/ajp-cell.00169.2003.
60. Watson JA, Watson CJ, McCann A, Baugh J. Epigenetics, the epicenter of the hypoxic response. Epigenetics 2010; 5:293-6; http://dx.doi.org/10.4161/epi.5.4.11684.
61. Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J, et al. Generation of an epigen-etic signature by chronic hypoxia in prostate cells. Hum Mol Genet 2009; 18:3594-604; http://dx.doi.org/10.1093/hmg/ddp307.
62. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypox-ia. Epigenetics 2007; 2:119-25; http://dx.doi.org/10.4161/epi.2.2.4613.
63. Skowronski K, Dubey S, Rodenhiser D, Coomber B. Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells. Epigenetics 2010; 5:547-56; http://dx.doi.org/10.4161/epi.5.6.12400.
64. Tausendschön M, Dehne N, Brüne B. Hypoxia causes epigenetic gene regulation in macrophages by attenuat-ing Jumonji histone demethylase activity. Cytokine 2011; 53:256-62; http://dx.doi.org/10.1016/j.cyto.2010.11.002.
65. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008; 372:892-7; http://dx.doi.org/10.1016/j.bbrc.2008.05.150.
66. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010; 30:344-53; http://dx.doi.org/10.1128/MCB.00444-09.
67. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-induc-ible factor HIF. J Biol Chem 2008; 283:36542-52; http://dx.doi.org/10.1074/jbc.M804578200.
68. Yang J, Ledaki I, Turley H, Gatter KC, Montero JC, Li JL, et al. Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. Ann N Y Acad Sci 2009; 1177:185-97; http://dx.doi.org/10.1111/j.1749-6632.2009.05027.x.
69. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43:811-22; http://dx.doi.org/10.1016/j.mol-cel.2011.07.012.